Oncorena Holding AB logo

Oncorena Holding AB

Oncorena develops a drug based on the natural substance orellanine, a highly kidney selective toxin from certain mushrooms. The therapeutic concept is to treat patients with metastasized renal clear cell cancer in dialysis with orellanine. Hereby the metastases will be destroyed. The ambition is to create a long-term survival benefit for the patients.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.oncorena.com
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Kullagatan 8, SE-252 20
Helsingborg
Sweden
Email
Contact Number
+ 46 (0)70 676 0008

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/oncorena-ab” connections=”true” suffix=””]